Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the SEC-registered offering of 10,222,222 shares of common stock of Stemline Therapeutics, Inc. for approximately $92 million. The common stock is listed on the NASDAQ Global Select Market under the symbol “STML.”
Stemline is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing innovative oncology therapeutics.
The Davis Polk capital markets team included partner Richard D. Truesdell Jr. and associate Win Rutherfurd. Partner David R. Bauer and associate Yifu Chen provided intellectual property and technology advice. All members of the Davis Polk team are based in the New York office.